Christopher specialises in assisting lawyers to enhance their skills, win new instructions, manage client relationships and augment their international networks.
He has worked in senior business development roles based in the UK and in Germany, and currently is the business development lead for the firm's Life Sciences & Healthcare industry sector.
Since 2019
Senior business development manager (Life sciences and healthcare), and Senior business development manager (Disputes and investigations, IP, Commercial tech and data, and Patents), Taylor Wessing
2011 - 2018
Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins
2001 - 2011
Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance
2001
Masters of business administration, International University, Germany
1996
M.A. in musicology, Michigan State University, US
1994
B.A. in German and B.A. in Music Performance, Michigan State University, US
Career
Since 2019
Senior business development manager (Life sciences and healthcare), and Senior business development manager (Disputes and investigations, IP, Commercial tech and data, and Patents), Taylor Wessing
2011 - 2018
Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins
2001 - 2011
Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance
Education
2001
Masters of business administration, International University, Germany
1996
M.A. in musicology, Michigan State University, US
1994
B.A. in German and B.A. in Music Performance, Michigan State University, US
Additional languages
German
Related news & insights
Banking & finance
Cabinet decision on the Statutory Health Insurance Contribution Stabilization Act – Financial burdens on German pharmaceutical companies
